Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands their pathology capabilities.
Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without chemotherapy.
Novartis will acquire Avidity Biosciences for $12 billion at $72 per share, gaining its RNA-targeting platform and neuroscience pipeline as Avidity spins off its precision cardiology programs into a new public company.
Kite, a life science company based in Santa Monica, will acquire Interius BioTherapeutics for $350 million to advance the development of in vivo CAR therapies.
Valencia-based biotech firm SetPoint Medical has raised $140 million in private financing to support the commercialization of its neuroimmune modulation therapy for rheumatoid arthritis.
Learn how Varda is pioneering “Zero-G Biology.” The space tech company just raised $187M to expand its mission of creating pharmaceuticals in low-Earth orbit.
Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights on AI, VC funding, and valuations.
Top executives from Axos Bank, Greenberg Traurig, and Vituity share key insights on leading through economic uncertainty, remote work, and digital transformation.
UC Irvine scientists developed bioluminescent RNA tags, “tiny guiding lights,” using luciferase to track RNA in real-time, potentially unlocking secrets of viruses and memory formation.
Vesicor Therapeutics, a San Gabriel-based biotech firm developing p53-based cancer treatments, is set to go public through a $70 million merger with SPAC Black Hawk Acquisition Corp. The combined entity will trade on Nasdaq as Vesicor Therapeutics and plans to advance its novel cancer drug towards U.S. clinical trials.
